1-2 of 2
Alessio Perrotti, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

Pier Luigi Zinzani, MD, PhD, Monica Tani, MD, Stefano Fanti, MD, Gerardo Musuraca, MD, Alessio Perrotti, MD, Umberto Vitolo, MD, Mariapaola Fina, MD, Barbara Botto, MD, Enrica Marchi, MD, Giulia Benevolo, MD, Vittorio Stefoni, MD, Michele Baccarani, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 2478.
https://doi.org/10.1182/blood.V108.11.2478.2478
Published: 2006
Journal Articles

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

Pier Luigi Zinzani, MD, PhD, Alessandro Pulsoni, MD, Manuela Balocco, MD, Monica Tani, MD, Stefano Fanti, MD, Alessio Perrotti, MD, Paolo Castellucci, MD, Francesco Zaja, MD, Alberto Fabbri, MD, Alfonso Zaccaria, MD, Maria Teresa Voso, MD, Pierpaolo Fattori, MD, Luciano Guardigni, MD, Patrizia Gentilini, MD, Maria Giuseppina Cabras, MD, Amalia De Renzo, MD, Luigi Rigacci, MD
Journal: Blood
Blood (2006) 108 (11): 2479.
https://doi.org/10.1182/blood.V108.11.2479.2479
Published: 2006